Free Trial

Black Diamond Therapeutics (BDTX) Competitors

Black Diamond Therapeutics logo
$3.24 -0.14 (-4.14%)
(As of 11/12/2024 ET)

BDTX vs. SPPI, CGEN, INBX, ITOS, CCCC, IGMS, TRDA, CRON, CRMD, and TRML

Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Spectrum Pharmaceuticals (SPPI), Compugen (CGEN), Inhibrx (INBX), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), Cronos Group (CRON), CorMedix (CRMD), and Tourmaline Bio (TRML). These companies are all part of the "medical" sector.

Black Diamond Therapeutics vs.

Black Diamond Therapeutics (NASDAQ:BDTX) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Black Diamond Therapeutics had 15 more articles in the media than Spectrum Pharmaceuticals. MarketBeat recorded 15 mentions for Black Diamond Therapeutics and 0 mentions for Spectrum Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.13 beat Spectrum Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Black Diamond Therapeutics Positive
Spectrum Pharmaceuticals Neutral

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Spectrum Pharmaceuticals shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 2.7% of Spectrum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spectrum Pharmaceuticals has higher revenue and earnings than Black Diamond Therapeutics. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A-$82.44M-$1.33-2.44
Spectrum Pharmaceuticals$10.11M20.91-$75.40M-$0.36-2.86

Black Diamond Therapeutics' return on equity of -68.08% beat Spectrum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Black Diamond TherapeuticsN/A -68.08% -49.65%
Spectrum Pharmaceuticals N/A -218.44%-66.16%

Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Black Diamond Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 378.40%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Spectrum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Diamond Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Spectrum Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Spectrum Pharmaceuticals received 436 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 62.36% of users gave Spectrum Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Black Diamond TherapeuticsOutperform Votes
51
69.86%
Underperform Votes
22
30.14%
Spectrum PharmaceuticalsOutperform Votes
487
62.36%
Underperform Votes
294
37.64%

Summary

Black Diamond Therapeutics beats Spectrum Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDTX vs. The Competition

MetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$183.32M$3.10B$5.20B$8.93B
Dividend YieldN/A1.72%7.15%4.02%
P/E Ratio-2.4447.81132.0718.10
Price / SalesN/A305.381,383.5575.05
Price / CashN/A176.1339.1736.30
Price / Book1.885.166.186.01
Net Income-$82.44M-$42.89M$117.66M$224.30M
7 Day Performance-0.31%1.51%1.74%3.67%
1 Month Performance-2.70%11.18%6.65%7.68%
1 Year Performance82.02%44.94%42.94%32.56%

Black Diamond Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDTX
Black Diamond Therapeutics
3.1288 of 5 stars
$3.24
-4.1%
$15.50
+378.4%
+82.0%$183.32MN/A-2.4490Earnings Report
Short Interest ↓
Positive News
SPPI
Spectrum Pharmaceuticals
N/A$1.03
flat
N/AN/A$211.41M$10.11M-2.8686
CGEN
Compugen
2.0676 of 5 stars
$1.78
flat
N/A+177.3%$158.84M$42.72M-17.8068Short Interest ↓
News Coverage
Gap Down
INBX
Inhibrx
3.853 of 5 stars
$16.32
+0.7%
N/A-13.2%$236.31M$1.63M0.00166Short Interest ↑
ITOS
iTeos Therapeutics
3.1432 of 5 stars
$9.66
+4.2%
N/A-3.9%$352.78M$12.60M-3.2290Analyst Forecast
Short Interest ↓
Gap Up
CCCC
C4 Therapeutics
2.0263 of 5 stars
$5.95
-1.8%
N/A+220.3%$420.01M$33.67M-3.50150Short Interest ↓
IGMS
IGM Biosciences
4.5814 of 5 stars
$12.59
-3.4%
N/A+151.7%$746.84M$2.13M-3.46190Earnings Report
Analyst Forecast
Short Interest ↓
News Coverage
TRDA
Entrada Therapeutics
1.7473 of 5 stars
$19.91
+0.5%
N/A+19.0%$745.03M$129.01M12.52110Gap Up
CRON
Cronos Group
2.081 of 5 stars
$1.93
-3.5%
N/A+9.7%$737.84M$87.24M-12.87356Short Interest ↓
News Coverage
Gap Up
CRMD
CorMedix
2.5196 of 5 stars
$12.04
+3.8%
N/A+262.4%$730.59M$60,000.00-14.8630Short Interest ↓
TRML
Tourmaline Bio
2.792 of 5 stars
$28.46
-1.0%
N/A+59.1%$729.71MN/A-10.0944Earnings Report
Analyst Forecast
Positive News

Related Companies and Tools


This page (NASDAQ:BDTX) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners